Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, 84100 Salerno, Italy.
Department of Health Sciences, University "Magna Græcia" of Catanzaro, 88100 Catanzaro, Italy.
Int J Mol Sci. 2023 Jan 27;24(3):2455. doi: 10.3390/ijms24032455.
Add-on biological therapy has proven to be effective in many patients with severe eosinophilic asthma. In this observational multicenter retrospective study, we report the results obtained with mepolizumab and benralizumab in severe asthmatics treated for 12 months in a real-life setting. In these patients, peripheral eosinophil levels, pulmonary function trends, exacerbation rates, systemic corticosteroid use, and symptom control were evaluated during the observation period, to understand which patients met all the criteria in order to be considered in disease remission. The percentage of remittent patients was 30.12% in the mepolizumab-treated subgroup, while in the benralizumab-treated subgroup, patients in complete disease remission were 40%, after 12 months. The results of this study confirm the efficacy of anti-IL-5 biologic drugs in the treatment of severe eosinophilic asthma in a real-life setting.
附加生物疗法已被证明对许多严重嗜酸粒细胞性哮喘患者有效。在这项观察性多中心回顾性研究中，我们报告了在现实环境中接受治疗 12 个月的重度哮喘患者使用美泊利珠单抗和贝那利珠单抗的结果。在此期间，评估了这些患者外周血嗜酸性粒细胞水平、肺功能趋势、恶化率、全身皮质类固醇的使用和症状控制情况，以了解哪些患者符合所有标准以被认为处于疾病缓解状态。在美泊利珠单抗治疗亚组中，缓解患者的百分比为 30.12%，而在贝那利珠单抗治疗亚组中，经过 12 个月，完全缓解疾病的患者比例为 40%。这项研究的结果证实了抗 IL-5 生物药物在真实环境中治疗严重嗜酸粒细胞性哮喘的疗效。
